The incidental discovery of pre-clinical interstitial lung disease (ILD) has led to the
designation of interstitial lung abnormalities (ILA), a radiological entity defined as the …

The Yes‐associated protein and its transcriptional coactivator with PDZ‐binding motif
(YAP/TAZ) are two homologous transcriptional coactivators that lie at the center of a key …

Dracocephalum Moldavica L. is a traditional herb for improving pharynx and relieving
cough. However, the effect on pulmonary fibrosis is not clear. In this study, we explored the …

Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary
fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. Placebo-controlled …

Background Pulmonary fibrosis (PF) is a respiratory disease with end-stage pathological
changes of interstitial lung disease that severely affects the survival of patients. Among the …

Drug development for idiopathic pulmonary fibrosis (IPF) has been challenging due to
poorly understood disease etiology, unpredictable disease progression, highly …

Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to
the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and …

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with a poor prognosis and
an unknown cause that generally progresses to pulmonary fibrosis and leads to irreversible …

Background Lower body mass index (BMI) and weight loss have been associated with
worse outcomes in some studies in patients with pulmonary fibrosis. We analyzed outcomes …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia
of unknown cause that is associated with radiological and/or histological features of usual …